ImaginAB and Eli Lilly announced a pre-clinical collaboration to use ImaginAb’s immune imaging agent IAB22M2C to study new T-cell therapies cancer. Continue reading
Tag Archives: CTL
Immatics and MD Anderson Collaborate on IL-21 for Cancer Immunotherapy
Immatics, a German biotechnology company has established a subsidiary in Houston, TX to collaborate with MD Anderson on overcoming some of the limitations to the adoptive T cell therapies now in the immuno-oncology pipeline. The collaboration covers the use of cytokine IL-21 to expand high-quality T cell batches, particularly those generated by CAR-T (chimeric antigen receptor T-cell) and related approaches. Continue reading
Cell Medica’s Antigen-Specific T-cells for Lymphoma
Cell Medica, a London-based biotech company, raised $78MM in a Series B financing with several accomplished biotech investors on the strength of data from its clinical trials in patients with EBV (Epstein Barr Virus) associated lymphomas. Continue reading
Immune Design files IPO for immuno-oncology CTL and T-helper platforms
Immune Design is the latest immuno-oncology company to file an Initial Public Offering to raise money to advance its platform technology and products. The company has 2 principal approaches to direct the immune system to fight cancer… Continue reading